T1N0M0乳腺癌的预后及系统辅助治疗  

Prognosis of T1N0M0 breast cancer and systemic adjuvant therapy

作　　者：董晓培 史业辉[1] DONG Xiaopei;SHI Yehui(Department of Breast Oncology,Tianjin Medical University Cancer Instituteand Hospital,National Clinical Research Center for Cancer,Tianjin's Clinical Research Center for Cancer,Key Laboratory of Cancer Prevention and Therapy,Tianjin,Key Laboratory of Breast Cancer Prevention and Therapy,Ministry of Education,Tianjin 300060,China)

机构地区：[1]天津医科大学附属肿瘤医院乳腺肿瘤内科,国家肿瘤临床医学研究中心,天津市恶性肿瘤临床医学研究中心,天津市“肿瘤防治”重点实验室,乳腺癌防治教育部重点实验室,天津300060

出　　处：《肿瘤》2021年第11期781-791,共11页Tumor

摘　　要：肿瘤大小和淋巴结转移状态被认为是影响乳腺癌预后的关键因素,因此T1N0M0乳腺癌通常被认为预后较好。然而,也有不少研究认为,肿瘤的组织学和病理学特征如激素受体(hormone receptor,HR)和人表皮生长因子受体2(human epidermal growth factor receptor 2,HER2)的表达状况、组织学分级和肿瘤细胞的增殖情况等,均与预后相关。同时,针对T1N0M0乳腺癌的治疗,目前各项指南的推荐方案并不一致。因此,如何综合上述各项因素以制定最优治疗方案,是目前围绕T1N0M0乳腺癌的最重要问题。本文针对这一问题进行系统阐述,以期对T1N0M0乳腺癌的临床治疗实践提供参考和指导。The tumor size and lymph node metastasis are the key factors affecting the prognosis of breast cancer,so T1N0M0 breast cancer is generally considered to have a favorite prognosis.However,many studies have shown that the histological and pathological characteristics of breast cancer,such as the expression of hormone receptor(HR) and human epidermal growth factor receptor 2(HER2),histological grade and tumor cell proliferation,are associated with prognosis.At the same time,for the treatment of T1N0M0 breast cancer,the current recommendations of various main guidelines are not consistent.Therefore,how to integrate the above various factors to make the optimal treatment decision is the most important problem about T1N0M0 breast cancer at present.This paper systematically expounds this problem in order to provide reference and guidance for the clinical treatment of T1N0M0 breast cancer.

关 键 词：乳腺肿瘤 T1N0M0 预后 治疗争议 

分 类 号：R73[医药卫生—肿瘤]